Efficacy
PD, Dara-refractory disease
DISEASE
Median follow-up ranged from 23.7 months in Cohort F3 to 63.0 months in Cohort A (Summary of response and survival.Atezo, atezolizumab; CI, confidence interval; CR, complete response; Dara, daratumumab; Dex, dexamethasone; DOR, duration of response; Len, lenalidomide; MR, minimal response; NE, not evaluable; NR, not reached; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PD, progressive disease; Pom, pomalidomide; PR, partial response; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response.*Cohort A: Atezo monotherapy; B1: Atezo+Len; C: Atezo+Len; D1/D2/D3: Atezo+Dara; E1: Atezo+Dara+Len; F1/F2: Atezo+Dara+Pom; F3: Dara+Pom+Dex.Median DOR was 45.2 months, 5.2 months and 16.5 months for Cohorts B1, D2 and F3, respectively and was not estimable for the remaining cohorts (Duration of response in all cohorts. D1/D2/D3: Atezo+Dara; E1: Atezo+Dara+Len; F1/F2: Atezo+Dara+Pom; F3: Dara+Pom+Dex. Atezo, atezolizumab; Dara, daratumumab; Dex, dexamethasone; Len, lenalidomide; Pom, pomalidomide.A small number of patients treated with Atezo+Dara, Atezo+Dara+Len, or Atezo+Dara+Pom (Cohorts D1, E1 and F1, respectively) demonstrated deep and durable responses, with 2 patients in Cohort D1 and 1 patient each in Cohorts E1 and F1 achieving long-lasting sCR. No responses to Atezo+Dara were observed in patients with Dara-refractory disease (Cohort D3), and the promising results in Cohort D1 did not propagate in the limited number of patients in D2 (ORR, 33%; CR, 0%) prior to study closure, with the caveats that patients in this cohort were older (median age: 64 years vs 59 years) and had a worse cytogenetic profile (high-risk cytogenetics: 73% vs 67%) than those in D1.